The first therapeutic effect data of VV116, a small-molecule oral drug for COVID-19 of Junshi Biosciences and Vigonvita, was released this week, captivating the industry.
The most encouraging news this week is that the international, multicenter, Phase III clinical trials of Hengrui's PD-1 combination therapy for liver cancer have been announced to be successful.
This week, the release of Phase III clinical data for treating outpatients infected with mild and moderate COVID-19 with Kintor Pharmaceuticals' proxalutamide sparked an intense interest. The pharma news review of this week covers a total of 18 pieces of